KR102384629B1 - 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성 - Google Patents

트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성 Download PDF

Info

Publication number
KR102384629B1
KR102384629B1 KR1020217034768A KR20217034768A KR102384629B1 KR 102384629 B1 KR102384629 B1 KR 102384629B1 KR 1020217034768 A KR1020217034768 A KR 1020217034768A KR 20217034768 A KR20217034768 A KR 20217034768A KR 102384629 B1 KR102384629 B1 KR 102384629B1
Authority
KR
South Korea
Prior art keywords
formula
compound
present
particular embodiment
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217034768A
Other languages
English (en)
Korean (ko)
Other versions
KR20210132745A (ko
Inventor
베노 로텐하우스러
레네 트루사르디
파비엔 호프만-에머리
우르스 슈비터
쟝-미쉘 아담
올라프 그라스만
토마스 하르퉁
프레데릭 란
랄프 디오돈
크리스토프 플레거
뵈른 바르텔스
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20210132745A publication Critical patent/KR20210132745A/ko
Application granted granted Critical
Publication of KR102384629B1 publication Critical patent/KR102384629B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1020217034768A 2013-12-05 2014-12-01 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성 Active KR102384629B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13195864.7 2013-12-05
EP13195864 2013-12-05
PCT/EP2014/076041 WO2015082370A1 (en) 2013-12-05 2014-12-01 Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
KR1020167017925A KR102384608B1 (ko) 2013-12-05 2014-12-01 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167017925A Division KR102384608B1 (ko) 2013-12-05 2014-12-01 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성

Publications (2)

Publication Number Publication Date
KR20210132745A KR20210132745A (ko) 2021-11-04
KR102384629B1 true KR102384629B1 (ko) 2022-04-11

Family

ID=49726573

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217034768A Active KR102384629B1 (ko) 2013-12-05 2014-12-01 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성
KR1020217034765A Active KR102384630B1 (ko) 2013-12-05 2014-12-01 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성
KR1020167017925A Active KR102384608B1 (ko) 2013-12-05 2014-12-01 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217034765A Active KR102384630B1 (ko) 2013-12-05 2014-12-01 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성
KR1020167017925A Active KR102384608B1 (ko) 2013-12-05 2014-12-01 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성

Country Status (19)

Country Link
US (3) US10246460B2 (https=)
EP (1) EP3077396B1 (https=)
JP (1) JP6454707B2 (https=)
KR (3) KR102384629B1 (https=)
CN (1) CN105793263B (https=)
AR (1) AR098592A1 (https=)
AU (2) AU2014359409A1 (https=)
CA (2) CA3142754C (https=)
ES (1) ES2875411T3 (https=)
HR (1) HRP20210966T1 (https=)
IL (2) IL245450A0 (https=)
MX (1) MX372971B (https=)
MY (1) MY175464A (https=)
NZ (1) NZ720340A (https=)
PL (1) PL3077396T3 (https=)
SG (1) SG11201604502SA (https=)
SI (1) SI3077396T1 (https=)
WO (1) WO2015082370A1 (https=)
ZA (1) ZA201603304B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6454707B2 (ja) 2013-12-05 2019-01-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ｔｒａｎｓ−８−クロロ−５−メチル−１−［４−（ピリジン−２−イルオキシ）−シクロヘキシル］−５，６−ジヒドロ−４Ｈ−２，３，５，１０ｂ−テトラアザ−ベンゾ［ｅ］アズレン及びその結晶形態の合成
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
BR112020004035A2 (pt) 2017-12-08 2020-09-01 F. Hoffmann-La Roche Ag formulação farmacêutica
WO2020139670A1 (en) 2018-12-27 2020-07-02 Teva Pharmaceuticals International Gmbh Solid state forms of balovaptan
WO2023059110A1 (ko) 2021-10-06 2023-04-13 주식회사 엘지에너지솔루션 배터리 모듈

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060836A1 (en) 2008-11-28 2010-06-03 F. Hoffmann-La Roche Ag Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197242A (en) * 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
KR100750028B1 (ko) * 2003-02-19 2007-08-16 화이자 인코포레이티드 치료에 유용한 트리아졸 화합물
GB0400700D0 (en) 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
CA2578370A1 (en) 2004-08-25 2006-03-02 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
RU2510397C2 (ru) * 2008-11-18 2014-03-27 Ф. Хоффманн-Ля Рош Аг Алкилциклогексиловые эфиры дигидротетраазабензоазуленов
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
PE20160203A1 (es) 2013-08-19 2016-04-20 Hoffmann La Roche Antagonistas de via para tratar trastornos del sueno por cambio de fase
JP6454707B2 (ja) * 2013-12-05 2019-01-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ｔｒａｎｓ−８−クロロ−５−メチル−１−［４−（ピリジン−２−イルオキシ）−シクロヘキシル］−５，６−ジヒドロ−４Ｈ−２，３，５，１０ｂ−テトラアザ−ベンゾ［ｅ］アズレン及びその結晶形態の合成

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060836A1 (en) 2008-11-28 2010-06-03 F. Hoffmann-La Roche Ag Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists

Also Published As

Publication number Publication date
ES2875411T3 (es) 2021-11-10
CA3142754C (en) 2024-01-02
CA2931016C (en) 2022-11-01
CN105793263A (zh) 2016-07-20
HK1223918A1 (zh) 2017-08-11
US20190194210A1 (en) 2019-06-27
ZA201603304B (en) 2022-05-25
JP6454707B2 (ja) 2019-01-16
CN105793263B (zh) 2019-08-23
US11040977B2 (en) 2021-06-22
AU2019201183A1 (en) 2019-03-14
JP2016539168A (ja) 2016-12-15
US20210284648A1 (en) 2021-09-16
KR102384630B1 (ko) 2022-04-11
IL245450A0 (en) 2016-06-30
AU2014359409A1 (en) 2016-05-19
CA3142754A1 (en) 2015-06-11
CA2931016A1 (en) 2015-06-11
WO2015082370A1 (en) 2015-06-11
US12459947B2 (en) 2025-11-04
KR20160093709A (ko) 2016-08-08
EP3077396B1 (en) 2021-04-21
RU2018135601A (ru) 2018-11-22
NZ759478A (en) 2021-06-25
US20160280712A1 (en) 2016-09-29
KR20210134985A (ko) 2021-11-11
HRP20210966T1 (hr) 2021-09-17
SG11201604502SA (en) 2016-07-28
IL264891B (en) 2021-02-28
US10246460B2 (en) 2019-04-02
PL3077396T3 (pl) 2021-10-04
AR098592A1 (es) 2016-06-01
RU2018135601A3 (https=) 2022-05-05
SI3077396T1 (sl) 2021-08-31
KR102384608B1 (ko) 2022-04-08
NZ720340A (en) 2020-03-27
AU2019201183B2 (en) 2021-03-04
MY175464A (en) 2020-06-29
MX2016006558A (es) 2016-08-03
KR20210132745A (ko) 2021-11-04
MX372971B (es) 2020-03-27
EP3077396A1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
AU2019201183B2 (en) Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
US10343993B2 (en) Processes and intermediates for the preparation of Pimavanserin
CN102985416B (zh) 制备凝血酶特异性抑制剂的方法
JP6268093B2 (ja) 縮合複素環誘導体の製造方法およびその製造中間体
US9815803B2 (en) Process for the preparation of substituted cycloserines
US10927095B2 (en) Processes for the preparation of Niraparib and intermediates thereof
WO2014020555A2 (en) An improved process for the preparation of dabigatran etexilate mesylate
RU2775690C2 (ru) Синтез транс-8-хлор-5-метил-1-[4-(пиридин-2-илокси)-циклогексил]-5,6-дигидро-4н-2,3,5,10в-тетраазабензо[e]азулена и его кристаллические формы
NZ759478B2 (en) Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof
EP3658569B1 (en) Process and intermediates for synthesis of peptide compounds
KR20070047798A (ko) 6,7-디하이드로-5Ｈ-이미다조[1,2-ａ]이미다졸-3-설폰산아미드의 합성
HK1223918B (zh) 一种苯并[e]薁化合物及其晶型的合成
EP2462144B1 (en) PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
KR20180018697A (ko) 테리플루노미드의 신규한 제조 공정
CN120289428A (zh) 一种1-氧代异吲哚啉衍生物及其应用
KR20180093307A (ko) 4, 5-디아미노 치환 피리미딘 유도체의 제조방법 및 이를 제조하기 위한 신규한 화합물

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5